Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark

BSE2038.6047.85 (+2.4 %)

PREV CLOSE ( ) 1990.75

OPEN PRICE ( ) 1992.10

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 13653

TODAY'S LOW / HIGH ( )1992.10 2042.00

52 WK LOW / HIGH ( )1274.7 2286.15

NSE2038.2046.1 (+2.31 %)

PREV CLOSE( ) 1992.10

OPEN PRICE ( ) 1997.90

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 2038.20 (257)

VOLUME 706599

TODAY'S LOW / HIGH( ) 1992.10 2042.70

52 WK LOW / HIGH ( )1275.5 2284.8

Chairman	Glenn Saldanha
Managing Director	Glenn Saldanha
Company Secretary	Harish Kuber
Non Executive Director	B E Saldanha
Non Executive Independent Director	Dipankar Bhattacharjee Saira Ramasastry Pradeep Kumar Sinha Vijayalakshmi Iyer Patricia Andrews
Whole Time Director	Anurag Mantri Cherylann Pinto

Incorporation Year : 18-11 1977

Registered Office :

Address : B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, Mumbai,
Maharashtra-400026 .

Phone :

Email : complianceofficer@glenmarkpharma.com

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE